Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Ocugen Receives FDA Orphan Drug Designation for OCU300 for Treatment of oGVHD

Ocugen, Inc., a clinical stage biopharmaceutical company developing novel treatments for sight-threatening diseases, today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for OCU300 (brimonidine tartrate) for the treatment of ocular graft versus host disease (oGVHD). Ocular GVHD is a common complication that occurs in 40-60 percent of patients who have undergone allergenic hematological stem cell transplantation (allo-SCT) or bone marrow transplants.